Lowering the TG/HDL-C ratio can prevent type 2 diabetes and type 2 diabetes.

Published Date: 17 Mar 2023

Iran: According to a study published in Diabetology and Metabolic Syndrome, triglycerides are elevated in normoglycemic patients.

Read Full News

Latest News

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Latest News

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

News All Time

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Q4 2026 Preview: 7 FDA Decisions to Watch

Q4 2026 Preview: 7 FDA Decisions to Watch

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Survey Shows Peptide Misinformation, Misuse Rising in US Ashish Rana, MD

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD Rajiv Agarwal, MD, MS

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Recommended News For You

A new way to measure suicide risk?

Liberalized Cannabis Policies May Increase Substance Use

A Lot Can Be Said About You by Including Yourself in Photos.

CAR-T Warning for Secondary Malignancies: Warranted or Not?

Alcohol Causes Cancer. We Should Be Drinking Less.

Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

Recommended Articles For You

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology 

Mechanisms of Tumor Cell Plasticity During Metastatic Spread 

Understanding SVR Normal Range: A Guide to Achieving Optimal Health 

Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

2.

Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.

3.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

4.

Study identifies new target for obesity-related breast cancer

5.

SBRT May Beat Brachytherapy in Prostate Cancer

1.

Precision Oncology Advances: Neoantigen Therapies, TCR Strategies & Radiotherapy Innovations

2.

Virtual Oncology Care Continuums: Transforming Cancer Management Through Digital Innovation

3.

AI Detection of Transfusion-Related Anomalies

4.

Molecular Classification of Treatment-Refractory Anemia

5.

Standards for Platelet Transfusion Stewardship

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

2.

Latest Advances in Hematology

3.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

4.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

5.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot